Myositis-specific Autoantibodies Are Specific for Myositis Compared to Genetic Muscle Disease

Overview

Journal Neurol Neuroimmunol Neuroinflamm

Specialty Neurology

Date 2015 Dec 16

PMID 26668818

Citations 21

Authors

Andrew L Mammen

Livia Casciola-Rosen

Lisa Christopher-Stine

Thomas E Lloyd

Kathryn R Wagner

Affiliations

Soon will be listed here.

Abstract

Objective: To determine the specificity of myositis-specific autoantibodies (MSAs) for autoimmune myopathy compared with inherited muscle diseases.

Methods: Serum samples from 47 patients with genetically confirmed inherited muscle diseases were screened for the most common MSAs, including those recognizing TIF1γ, NXP2, Mi2, MDA5, Jo1, SRP, and HMGCR. We compared these results with the findings in a cohort of patients with dermatomyositis (DM) previously screened for anti-TIF1γ, -NXP2, -Mi2, -MDA5, and -Jo1.

Results: Overall, the presence of anti-TIF1γ, -NXP2, -Mi2, -MDA5, or -Jo1 was 96% specific and 67% sensitive for DM compared to patients with genetic muscle diseases. No patients with inherited muscle disease had anti-SRP or anti-HMGCR autoantibodies. Only 2 patients with genetic muscle disease had a MSA. One patient with anti-Mi2 autoantibodies had both genetically confirmed facioscapulohumeral dystrophy and dermatomyositis based on a typical skin rash and partial response to immunosuppressive medications. A second patient with anti-Jo-1 autoantibodies had both genetically defined limb-girdle muscular dystrophy type 2A (i.e., calpainopathy) and a systemic autoimmune process based on biopsy-confirmed lupus nephritis, sicca symptoms, and anti-Ro52 autoantibodies.

Conclusions: The MSAs tested for in this study are highly specific for autoimmune muscle disease and are rarely, if ever, found in patients who only have genetic muscle disease. In patients with genetic muscle disease, the presence of a MSA should suggest the possibility of a coexisting autoimmune process.

Citing Articles

The diagnostic journey of patients being investigated for myopathy in a tertiary centre in England.

Qiang Z, Barnett L, Bingham G, Han O, Walsh A, Conwill M J Neurol. 2024; 272(1):35.

PMID: 39666128 PMC: 11638302. DOI: 10.1007/s00415-024-12737-y.

Absence of Pathogenic Mutations and Strong Association With HLA-DRB1*11:01 in Statin-Naïve Early-Onset Anti-HMGCR Necrotizing Myopathy.

Llanso L, Segarra-Casas A, Dominguez-Gonzalez C, Malfatti E, Kapetanovic S, Rodriguez-Santiago B Neurol Neuroimmunol Neuroinflamm. 2024; 11(5):e200285.

PMID: 39106428 PMC: 11309561. DOI: 10.1212/NXI.0000000000200285.

Statin-Induced Immune-Mediated Necrotizing Myopathy Resulting in Proximal Muscle Weakness.

Abdalla M, Zhang Q, Abdalla M, Abdel-Jalil S J Med Cases. 2023; 14(2):64-70.

PMID: 36896367 PMC: 9990704. DOI: 10.14740/jmc4039.

Becker Muscular Dystrophy Accompanied by Anti-HMGCR Antibody-positive Immune-mediated Necrotizing Myopathy.

Munekane A, Ohsawa Y, Okubo M, Nagai T, Nishimura H, Nishino I Intern Med. 2022; 62(9):1345-1349.

PMID: 36130887 PMC: 10208778. DOI: 10.2169/internalmedicine.0202-22.

Systemic sclerosis in a patient with muscle dystrophy.

Moutinho-Pereira S, Morais-de-Sa E, Greenfield H, Pereira P BMJ Case Rep. 2022; 15(9).

PMID: 36100284 PMC: 9472154. DOI: 10.1136/bcr-2022-250389.

References

Amato A, Griggs R . Unicorns, dragons, polymyositis, and other mythological beasts. Neurology. 2003; 61(3):288-9. DOI: 10.1212/wnl.61.3.288. View

Hoogendijk J, Amato A, Lecky B, Choy E, Lundberg I, Rose M . 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004; 14(5):337-45. DOI: 10.1016/j.nmd.2004.02.006. View

Mohassel P, Rosen P, Casciola-Rosen L, Pak K, Mammen A . Expression of the dermatomyositis autoantigen transcription intermediary factor 1γ in regenerating muscle. Arthritis Rheumatol. 2014; 67(1):266-72. PMC: 4280343. DOI: 10.1002/art.38863. View

van der Meulen M, Bronner I, Hoogendijk J, Burger H, van Venrooij W, Voskuyl A . Polymyositis: an overdiagnosed entity. Neurology. 2003; 61(3):316-21. DOI: 10.1212/wnl.61.3.316. View

Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E . Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med. 2005; 201(4):591-601. PMC: 2213068. DOI: 10.1084/jem.20041367. View

Pinal-Fernandez I, Casciola-Rosen L, Christopher-Stine L, Corse A, Mammen A . The Prevalence of Individual Histopathologic Features Varies according to Autoantibody Status in Muscle Biopsies from Patients with Dermatomyositis. J Rheumatol. 2015; 42(8):1448-54. PMC: 6544046. View

Casciola-Rosen L, Mammen A . Myositis autoantibodies. Curr Opin Rheumatol. 2012; 24(6):602-8. PMC: 3874450. DOI: 10.1097/BOR.0b013e328358bd85. View

Rider L, Miller F . Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA. 2011; 305(2):183-90. PMC: 4047218. DOI: 10.1001/jama.2010.1977. View

Claeys K, Gorodinskaya O, Handt S, Reimann J, Kress W, Kornblum C . Diagnostic challenge and therapeutic dilemma in necrotizing myopathy. Neurology. 2013; 81(10):932-5. DOI: 10.1212/WNL.0b013e3182a35285. View

10.

Mammen A . Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci. 2010; 1184:134-53. DOI: 10.1111/j.1749-6632.2009.05119.x. View

11.

Mammen A, Casciola-Rosen L, Hall J, Christopher-Stine L, Corse A, Rosen A . Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum. 2009; 60(12):3784-93. PMC: 2828900. DOI: 10.1002/art.24977. View

12.

Hengstman G, van Brenk L, Vree Egberts W, van der Kooi E, Borm G, Padberg G . High specificity of myositis specific autoantibodies for myositis compared with other neuromuscular disorders. J Neurol. 2005; 252(5):534-7. DOI: 10.1007/s00415-005-0683-5. View

13.

Mammen A, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering K . Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011; 63(3):713-21. PMC: 3335400. DOI: 10.1002/art.30156. View

14.

Fiorentino D, Chung L, Christopher-Stine L, Zaba L, Li S, Mammen A . Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum. 2013; 65(11):2954-62. PMC: 4073292. DOI: 10.1002/art.38093. View

15.

Christopher-Stine L, Casciola-Rosen L, Hong G, Chung T, Corse A, Mammen A . A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010; 62(9):2757-66. PMC: 3026777. DOI: 10.1002/art.27572. View